Tag: Amgen

With an estimated cost of a full course reaching hundreds of thousands of dollars before insurance, understanding how much Tepezza costs is crucial for patients with Thyroid Eye Disease. This breakthrough medication's final price is heavily influenced by insurance, dosage, and financial assistance programs.

First approved by the FDA in 1997, rituximab has since revolutionized the treatment of several B-cell cancers and autoimmune diseases. The journey to market involved multiple companies, and today, an expanding list of manufacturers produce this essential medicine. So, which company makes rituximab, and what do you need to know about the different versions?

Since its FDA approval in 2018, Aimovig (erenumab-aooe) has been a key player in migraine prevention [1.2.5]. Despite rumors, if you're asking 'Why was Aimovig discontinued?', the simple answer is: it hasn't been. The confusion stems from a significant change in its commercial partnership.

The list price for a single 1.0 mL vial of Krystexxa, an advanced treatment for chronic gout, can exceed $30,000, making the question of **how much does krystexxa cost** a critical one for patients. The actual price a patient pays, however, is heavily dependent on insurance coverage and manufacturer support programs.

In 2006, the U.S. Food and Drug Administration granted approval to panitumumab (brand name Vectibix) for the treatment of certain patients with metastatic colorectal cancer. The current owner of panitumumab is the global biotechnology company Amgen Inc., following a key acquisition that secured its intellectual property and commercial rights.

Originally developed by Amgen, the biologic medication brodalumab underwent several key ownership changes before its market debut, creating a complex manufacturing and commercialization landscape. The answer to who makes brodalumab depends heavily on the geographic region, as different pharmaceutical companies hold marketing rights in different parts of the world.

As of mid-2025, pharmaceutical manufacturer Amgen is phasing out certain delivery systems for its cholesterol-lowering medication, Repatha, leaving many patients to wonder: **Why are they discontinuing Repatha?** This decision specifically affects the Pushtronex System and standard prefilled syringes, but it is not due to any safety or efficacy issues with the drug itself.

Originally developed by Abgenix Inc., Vectibix (panitumumab) has been manufactured and commercialized by the biopharmaceutical company Amgen Inc. since it acquired Abgenix in 2006. This acquisition gave Amgen full ownership and control over the drug, solidifying its role in bringing this important metastatic colorectal cancer treatment to market.

In a Phase 1 study of 97 patients with metastatic castration-resistant prostate cancer, 49% experienced a significant drop in prostate-specific antigen levels after treatment with xaluritamig [1.2.3]. So, **what is amg 509** and how does this promising immunotherapy work?

In a clinical study published in *Cancer Discovery*, 49% of heavily pretreated patients with metastatic castration-resistant prostate cancer experienced a significant reduction in prostate-specific antigen (PSA) levels with the experimental immunotherapy Xaluritamig. This article explores this promising new treatment strategy and its role in oncology.